Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 4,400 shares, a growth of 46.7% from the January 15th total of 3,000 shares. Based on an average trading volume of 13,300 shares, the days-to-cover ratio is currently 0.3 days.
Adlai Nortye Trading Down 2.2 %
Adlai Nortye stock opened at $2.25 on Friday. The stock has a fifty day moving average price of $2.16 and a 200 day moving average price of $2.38. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Adlai Nortye in a research report on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
- Five stocks we like better than Adlai Nortye
- Using the MarketBeat Dividend Yield Calculator
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Find and Profitably Trade Stocks at 52-Week Lows
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- The Significance of Brokerage Rankings in Stock Selection
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
